Keros Therapeutics (KROS) EBIT Margin (2019 - 2025)
Keros Therapeutics (KROS) posted EBIT Margin of -7602.60% for Q4 2025, down 5851.97 percentage points from -1750.62% a year earlier and down 7494.73 percentage points from the prior quarter.
Powered by 
Analysis
Keros Therapeutics (KROS) EBIT Margin (2019 - 2025) Analysis & Trends
For FY2025, Keros Therapeutics' EBIT Margin came in at 27.69%, up 5966.64 percentage points from FY2024.
- Annual EBIT Margin shows a four-year change of +308.15 percentage points (FY2021 to FY2025).
- In prior years, Keros Therapeutics' EBIT Margin was -5938.96% in FY2024 (+106604.75 pp), -112543.71% in FY2023 and -280.46% in FY2021.
- The Q4 2025 figure stands as the lowest quarterly EBIT Margin since Q3 2024.
- On a year-over-year basis, EBIT Margin increased in five of the last six quarters, with an average year-over-year change of +126727.21 percentage points.
- According to Business Quant data, EBIT Margin for the three prior quarters was -107.87% (Q3 2025), -219.16% (Q2 2025) and 71.97% (Q1 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,130.22 Bn | 1,098.81 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 613.62 Bn | 532.15 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 501.46 Bn | 474.57 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 366.84 Bn | 321.22 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 297.85 Bn | 261.84 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 235.39 Bn | 190.79 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 169.57 Bn | 116.22 Bn | 10.94 Bn | 28.37% |
| 10 | Keros Therapeutics | 226.12 Mn | -1.70 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -7,602.60% |
| Sep 30, 2025 | -107.87% |
| Jun 30, 2025 | -219.16% |
| Mar 31, 2025 | 71.97% |
| Dec 31, 2024 | -1,750.62% |
| Sep 30, 2024 | -15,117.78% |
| Jun 30, 2024 | -136,321.62% |
| Mar 31, 2024 | -58,413.25% |
| Dec 31, 2023 | -32,486.01% |
| Sep 30, 2023 | -541,000.00% |
| Mar 31, 2022 | -134.03% |
| Dec 31, 2021 | -24.33% |
| Jun 30, 2021 | -15,541.00% |
| Dec 31, 2019 | -109.12% |
| Sep 30, 2019 | -93.04% |
| Jun 30, 2019 | -106.04% |
| Mar 31, 2019 | -114.32% |
API Access
Keros Therapeutics EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=KROS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "KROS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=KROS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();